BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20609590)

  • 1. Efficient synthesis of Hsp90 inhibitor dimers as potential antitumor agents.
    Sekiguchi H; Muranaka K; Osada A; Ichikawa S; Matsuda A
    Bioorg Med Chem; 2010 Aug; 18(15):5732-7. PubMed ID: 20609590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of Hsp90 inhibitor dimers as potential antitumor agents.
    Muranaka K; Sano A; Ichikawa S; Matsuda A
    Bioorg Med Chem; 2008 Jun; 16(11):5862-70. PubMed ID: 18487051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.
    Immormino RM; Kang Y; Chiosis G; Gewirth DT
    J Med Chem; 2006 Aug; 49(16):4953-60. PubMed ID: 16884307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery.
    Audisio D; Messaoudi S; Cegielkowski L; Peyrat JF; Brion JD; Methy-Gonnot D; Radanyi C; Renoir JM; Alami M
    ChemMedChem; 2011 May; 6(5):804-15. PubMed ID: 21374821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally active purine-based inhibitors of the heat shock protein 90.
    Biamonte MA; Shi J; Hong K; Hurst DC; Zhang L; Fan J; Busch DJ; Karjian PL; Maldonado AA; Sensintaffar JL; Yang YC; Kamal A; Lough RE; Lundgren K; Burrows FJ; Timony GA; Boehm MF; Kasibhatla SR
    J Med Chem; 2006 Jan; 49(2):817-28. PubMed ID: 16420067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
    Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
    J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
    Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
    Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
    Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
    Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies.
    Day JE; Sharp SY; Rowlands MG; Aherne W; Lewis W; Roe SM; Prodromou C; Pearl LH; Workman P; Moody CJ
    Chemistry; 2010 Sep; 16(34):10366-72. PubMed ID: 20661961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
    Burlison JA; Blagg BS
    Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation.
    Kimura H; Yukitake H; Tajima Y; Suzuki H; Chikatsu T; Morimoto S; Funabashi Y; Omae H; Ito T; Yoneda Y; Takizawa M
    Chem Biol; 2010 Jan; 17(1):18-27. PubMed ID: 20142037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.